Brief: Shanghai Henlius Biotech Announces License Agreement With Eisai
05/02/2026 10:16
Feb 5 (Reuters) - Shanghai Henlius Biotech Inc 2696.HK: LICENSE AGREEMENT WITH EISAI IN RESPECT OF HANSIZHUANG GRANTED EISAI CO LICENSE TO DEVELOP, MANUFACTURE & COMMERCIALISE HANSIZHUANG EISAI TO PAY HENLIUS $75 MILLION UPFRONT FEE, UPON EXECUTION OF LICENSE AGREEMENT EISAI TO PAY UP TO $233.33 MILLION IN COMMERCIAL SALES MILESTONES, OTHERS Further company coverage: 2696.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eisai
See all newsBiogen tops quarterly estimates on rare-disease drug strength (updated)
Biogen beats third-quarter results on strength in rare disease drugs
Brief: FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
Leqembi Pen (Subcutaneous Formulation Of Leqembi) Approved In Japan
Leqembi (Lecanemab) Subcutaneous Formulation As An Initiation Treatment For Early Alzheimer's Disease Approved In China